Sociedad Española de Reumatología-ko ikertzaileekin lankidetzan egindako argitalpenak (10)

2024

  1. Cancer risk with biologic and targeted synthetic DMARDs in patients with rheumatic diseases and previous malignancies: Results from the BIOBADASER register

    Seminars in Arthritis and Rheumatism, Vol. 64

2023

  1. Effects of COVID-19 vaccination on disease activity in patients with rheumatoid arthritis and psoriatic arthritis on targeted therapy in the COVIDSER study

    RMD open, Vol. 9, Núm. 1

2022

  1. Prevalence of post-COVID-19 in patients with fibromyalgia: a comparative study with other inflammatory and autoimmune rheumatic diseases

    BMC Musculoskeletal Disorders, Vol. 23, Núm. 1

  2. The reality of Rheumatology in Spain and its autonomous communities before the pandemic

    Reumatologia Clinica, Vol. 18, Núm. 8, pp. 486-489

2020

  1. Clinical features and outcomes of COVID-19 in patients with rheumatic diseases treated with biological and synthetic targeted therapies

    Annals of the Rheumatic Diseases

2015

  1. Actualización 2014 del Documento de Consenso de la Sociedad Española de Reumatología sobre el uso de terapias biológicas en la artritis reumatoide

    Reumatologia Clinica, Vol. 11, Núm. 5, pp. 279-294

2010

  1. Update of the Consensus Statement of the Spanish Society of Rheumatology on the management of biologic therapies in rheumatoid arthritis

    Reumatologia Clinica, Vol. 6, Núm. 1, pp. 23-36

2007

  1. Registro Español de Acontecimientos Adversos de Terapias Biológicas en Enfermedades Reumáticas (BIOBADASER): Informe de la situación, 26 de enero de 2006

    Reumatologia Clinica, Vol. 3, Núm. 1, pp. 4-20

2006

  1. Switching TNF antagonists in patients with chronic arthritis: An observational study of 488 patients over a four-year period

    Arthritis Research and Therapy, Vol. 8, Núm. 1

2001

  1. Sociedad Española de reumatología. Uso de coxibs

    Revista Espanola de Reumatologia, Vol. 28, Núm. 8, pp. 341-342